Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public











Title  Creator  Group name  Publishing year 
Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial Vano et al. EquipeCG 2022-05
Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma: The CABIR study Vano et al. EquipeCG 2022-10-15
Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study Flippot et al. EquipeCG Aug 10, 2019
Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next? Bersanelli et al. EquipeCG Jul 19, 2019
Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial Oudard et al. EquipeCG May 01, 2019
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer Smith et al. EquipeCG Apr 12, 2018
Tim-3 Expression on Tumor-Infiltrating PD-1+CD8+T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma Granier et al. EquipeJC Mar 01, 2017


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés